The GYG1 Knockout HCT 116 Polyclonal Cells are a mixed population of HCT 116 cells with CRISPR/Cas9-mediated disruption of the GYG1 gene, encoding glycogenin-1. This polyclonal knockout pool lacks glycogenin-1 function, providing a heterogeneous model that avoids clonal selection bias and mirrors natural genetic variation. By abolishing glycogen primer synthesis, these cells enable dissection of glycogen metabolism and its integration with cellular signaling.
The host HCT 116 cell line is a widely utilized human epithelial colorectal carcinoma model, characterized by activating KRAS mutation and mismatch repair deficiency due to MLH1 inactivation, leading to microsatellite instability (MSI) and a near-diploid karyotype. This genetic background renders HCT 116 cells highly relevant for investigating colorectal cancer biology, including tumor metabolism, drug resistance, and signaling pathway dependencies. Their adherent growth and well-characterized genomic landscape make them a dependable platform for gene editing studies aimed at understanding metabolic rewiring in cancer.
Glycogenin-1 (GYG1) is the core glycosyltransferase that initiates glycogen synthesis via autoglucosylation, generating a short glucose primer for elongation by glycogen synthase (GYS1) and branching enzyme (GBE1). Its expression is driven by insulin/IGF-1 signaling through transcription factors FOXO1 and MEF2, while AMPK negatively regulates glycogenesis under energetic stress. GYG1 directly binds GYS1, UDP-glucose, and GBE1 to seed glycogen particles. Downstream pathway components include UGP2, PYGL, and PPP1R3C. Knockout of GYG1 abolishes primer formation, preventing GYS1-mediated glycogen accumulation and disrupting cellular glycogen stores.
In HCT 116 colorectal carcinoma, KRAS-driven metabolic reprogramming may enhance glycogenic flux, making the GYG1 knockout model valuable for assessing how glycogen reserves support proliferation and stress survival. Colorectal tumors frequently face hypoxia and nutrient scarcity; glycogen can act as an energy buffer. Loss of glycogenin-1 in this MSI KRAS-mutant background permits systematic investigation of glycogen dependency in cancer cells and identification of compensatory metabolic pathways. This model also bridges glycogen storage disease biology with oncogenic metabolism.
Key assays employing these cells include PAS staining for glycogen visualization, western blot and RT-qPCR for GYG1 expression, and glucose uptake or ATP measurements to evaluate metabolic impact. They support hypoxia response studies, cell proliferation readouts, and drug sensitivity screens targeting metabolic pathways. Metabolic flux analysis can trace glucose incorporation into glycogen and glycolytic intermediates, revealing compensatory shifts. This polyclonal knockout model thus serves as a versatile platform for probing glycogen biology in cancer and for translational research. For technical inquiries, please contact Ascent Research.
